Tanaleon, Jenelyn .
HRN: 24-15-56 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/14/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
12/14/2024
12/15/2024
IVT
500mg
Q8
G1P0; Thickly MSAF
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes